64Cu-DOTATATE PET for Neuroendocrine Tumors: a Prospective Head-to-Head Comparison with 111In-DTPA-octreotide in 112 Patients

Research output: Contribution to journalJournal article – Annual report year: 2015Researchpeer-review

Documents

DOI

  • Author: Pfeifer, Andreas Klaus

    Copenhagen University Hospital, Denmark

  • Author: Knigge, Ulrich

    Copenhagen University Hospital, Denmark

  • Author: Binderup, Tina

    University of Copenhagen, Denmark

  • Author: Mortensen, Jann

    Copenhagen University Hospital, Denmark

  • Author: Oturai, Peter

    Copenhagen University Hospital, Denmark

  • Author: Loft, Annika

    Copenhagen University Hospital, Denmark

  • Author: Berthelsen, Anne Kiil

    Copenhagen University Hospital, Denmark

  • Author: Langer, Seppo Wang

    Copenhagen University Hospital

  • Author: Rasmussen, Palle

  • Author: Elema, Dennis Ringkjøbing

    The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Frederiksborgvej 399, 4000, Roskilde, Denmark

  • Author: von Benzon, Eric

    Copenhagen University Hospital, Denmark

  • Author: Højgaard, Liselotte

    Copenhagen University Hospital, Denmark

  • Author: Kjær, Andreas

    Copenhagen University Hospital, Denmark

View graph of relations

Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.
METHODS:

We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance.
RESULTS:

Eighty-seven patients were congruently PET- and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017). In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC.
CONCLUSION:

With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.
Original languageEnglish
JournalJournal of Nuclear Medicine
Volume56
Issue number6
Pages (from-to)847-854
ISSN0161-5505
DOIs
Publication statusPublished - 2015
CitationsWeb of Science® Times Cited: No match on DOI

Download statistics

No data available

ID: 112569560